NeurologyLive Friday 5 — May 28, 2021

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 28, 2021.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: ALS Research and Care: What Can We Look Forward To?

Matthew B. Harms, MD, associate professor of neurology at Columbia and medical consultant for the Muscular Dystrophy Association, shares his thoughts on the current state of ALS care, the role of patient registries, the future use of telemedicine in neuromuscular disorders, and the need for speed in ALS diagnosis.

2: AHA Updates Guidelines for Secondary Stroke Prevention, Risk Factor Mitigation

The American Heart Association/American Stroke Association has published updated guidelines for the prevention of secondary stroke, focusing on diagnostics, managing vascular and lifestyle factors, patient behaviors, antithrombotic therapy, atrial fibrillation monitoring, and a number of other topics.

3: NeuroVoices: Barry Hendin, MD, on World MS Day and Trends in MS Care

Ahead of #WordMSDay on May 30, the neurologist from Banner Health and chief medical officer of the MS Association of America discussed the significance of World MS Day, how clinical care of MS has evolved, and what research developments that he is keeping his eye on in the coming months.

4: Investigating Disparities in Post-Stroke Rehabilitation

Sana Somani, MD, MBBS, vascular neurology fellow at the University of Maryland Medical Center, discussed her research into disparities in post-stroke care, the factors that contribute to these disparities, and how rehabilitation efficacy could be improved for these groups that have lower functional independence scores.

5: Peer Exchange: Ongoing Clinical Trials and the Future of ALS

In this segment of the NeurologyLive Peer Exchange, "Progress in the Treatment of Amyotrophic Lateral Sclerosis," key opinion leaders Richard S. Bedlack, MD, PhD, MS; Ammar Al-Chalabi, MB, ChB, PhD; Jinsy A. Andrews, MD, MSc; and Jeremy M. Schefner, MD, PhD, review the study design and mechanisms of action for drugs in ongoing clinical trials and consider the future of amyotrophic lateral sclerosis.

–––––––––

If you missed your chance to see the May broadcast of our free webinar series, "The Ever-Changing Face of Multiple Sclerosis," put on in partnership with the Consortium of Multiple Sclerosis Centers, don't fret! You can join Ahmed Obeidat, MD, PhD; Mitch Freedman, MD; and Suma Shah, MD, and others as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.

To view the enduring version of either of the first two programs, click here for our Future Leaders in Neurology section.